ClinicalTrials.gg
Sign In
RecruitingNCT04581928Updated Sep 6, 2023

Patients Reactions Towards Their Diagnosis as Having COVID-19

An observational study in Covid19, sponsored by ClinAmygate. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by ClinAmygate · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
3,812
Ages
18 Years and older
Sex
All
01

Study summary

Patients reactions towards their diagnosis as having COVID-19. The effect of patients' reaction toward their prospect management. How this can make many hazards. Also, obstacle and barrier to better management.

Read the detailed description

Patients reactions towards their diagnosis as having COVID-19. The effect of patients' reaction toward their prospect management. How this can make many hazards. Also, obstacle and barrier to better management.

Different factors affecting the response of people toward their diagnosis as COVID-19

02

Conditions studied

  • Covid19

Browse trials for

03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's planned enrollment of 3,812 is above the median of 268 across 3,208 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ClinAmygate is the lead sponsor of 18 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All COVID-19 cases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COVID-19
  • Age 18 years of less

Exclusion criteria

Exclusion Criteria:

  • Mental diseases making the communication with them difficult
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
3,812 participants (estimated)
Patient registry
No

Groups and cohorts

  • COVID-19

    Highly educated people Low educated people

06

What researchers measure

Primary outcomes

  1. Time to recovery

    Time needed to recovery from symptoms of covid-19

    Time frame: Four weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wiseman EJ. Denial in the medical interview. JAMA. 1995 Jun 14;273(22):1735; author reply 1735-6. doi: 10.1001/jama.273.22.1735. No abstract available. PubMed 7769754 ↗

Individual participant data

Plan to share: No — Individual data will not shared as per local regulations

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04581928
Lead sponsor
ClinAmygate
Responsible party
Emad R Issak (Doctor, ClinAmygate) — Principal investigator
First posted
Oct 9, 2020
Start date
Oct 10, 2020
Primary completion
Oct 10, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Sep 6, 2023

Study contacts

Emad R Issak, MD
Contact
dr.emad.r.h.issak@gmail.com
01272228989
Emad R Issak, MD
principal investigator · Assalam Clinics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19 →

Other studies from this sponsor

ClinAmygate

Start the discussion